Insights from 2023 ASH Annual Meeting
Playback speed
10 seconds
Video Player is loading.
Current Time 0:00
/
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time -0:00
1x
- 0.5x
- 0.75x
- 1x, selected
- 1.25x
- 1.5x
- 1.75x
- 2x
- Chapters
- descriptions off, selected
- captions settings, opens captions settings dialog
- captions off, selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
ASH 2023 Insights: "MRD-Guided Acalabrutinib, Venetoclax and Obinutuzumab in R/R CLL From the CLL2-BAAG Trial"
By
Insights from 2023 ASH Annual Meeting
FEATURING
Moritz Fürstenau
By
Insights from 2023 ASH Annual Meeting
FEATURING
Moritz Fürstenau
61 views
December 29, 2023
Comments 0
Login to view comments.
Click here to Login
Leukemia